İsteğe bağlı ürün analizi
İzninizle, hangi araştırma yolculuklarının işe yaradığını anlamak için gizliliği gözeten sınırlı analizler kullanırız. Reklam izleyicileri veya oturum kaydı kullanmayız. Bu seçimi Tercihler bölümünden değiştirebilirsiniz. Okuyun Gizlilik Politikası.
FY2027 revenue above $40.21 billion and adjusted EPS approaching $26.33 would extend the earnings path while strong cash generation supports reinvestment and debt service.
FY2027 adjusted diluted EPS falls below $22.57.
Buy. At $437.23 on 2026-09-04, the shares were below Fair value of $492.07 and Potential value of $640.92.3
The main risk is customer concentration. Repricing, loss, or in-sourcing by a major customer could reduce product sales, profit, and cash together.6
The clearest upside is stronger FY2027 revenue and adjusted with continued cash backing. That combination would extend earnings growth and raise value per share.
The demand-led upside case requires FY2027 revenue to exceed its $40.21 billion mean while adjusted earnings remain strong.1
Buy because the report-date price sits below Fair value and positive FY2027 estimates have support from strong cash generation.35
Buy because the report-date price sits below Fair value and positive FY2027 estimates have support from strong cash generation.35
Amgen Inc. operates in a highly competitive environment. A number of its marketed products are indicated for disease areas in which other products or treatments are currently available or are being pursued by its competitors through R&D activities.
Additionally, some competitor-marketed products target the same genetic pathways as its recently launched marketed products or product candidates. Amgen Inc. provides negotiated rebates or discounts to healthcare providers, private payers, government payers and PBMs.
A customer event causing a 5% annual product-revenue contraction would reduce consolidated sales and pressure profit before leverage effects.
Adjusted diluted EPS below $22.57 would show that the explicit earnings path and its assumed duration are not deliverable.1
A rise exceeding two percentage points from the 7.6252% cost-of-equity baseline would reduce the present worth of distant earnings.
Yatırım tezimizi zayıflatacak beş gelişme.
A breach would show that the explicit earnings bridge failed, shortening the supported earnings period and reducing value assigned to future profit.
Güncel:FY2027 mean of $24.41 as of 2026-09-08.
Şu durumda uyarBelow $22.57 by FY2027.
The evidence does not establish a structural moat based on switching costs, protected distribution, or platform breadth. Strong cash generation is an outcome, not a source of customer lock-in.
Product revenue supplied 95.6% of FY2025 revenue, while three customers supplied 77%. This concentration limits evidence for durable pricing power.
Cash generation supports present economics, but it does not establish durable excess returns.45
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
The highlighted cell is Fair value when every assumption sits at its base level ($492.07). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $11.2B after modeled capex of $1.9B, with terminal value at 69.9% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
Moderate growth and continued cash backing support the central valuation outlook. Evidence should emerge by FY2027 through annual revenue and adjusted EPS delivery.
Stronger sales and earnings would support a longer period of growth.
That result would preserve the base path without proving longer-term durability.
A miss would shorten supported earnings duration.
FY2025 operating cash flow exceeded reported net income, but substantial debt still limits financial flexibility.35
FY2025 free cash flow remained positive after $1.86 billion of capital spending. This supports the earnings case, although future growth investment is not assumed to be costless.45
Shares outstanding were 540.632 million on 2026-09-08 versus 542 million diluted-average shares in FY2025. The outlook retains dilution rather than assuming a buyback benefit.
The cash figures support operating strength, but they do not establish a dated return-on-invested-capital trajectory.
No ROIC comparison is asserted. The enterprise discount rate was 7.1098% as of 2026-09-08.
FY2025 operating cash flow was $9.96 billion and free cash flow was $8.1 billion.
Cash supports investment and debt service, but does not remove leverage risk.
FY2025 net income was $7.71 billion, below operating cash flow.
The earnings case is less dependent on non-cash accounting entries.
| Gelir | $36.751.000.000 |
|---|---|
| Satışların maliyeti | $10.739.000.000 |
| Brüt kâr | $26.012.000.000 |
| Faaliyet giderleri | $16.932.000.000 |
| Faaliyet kârı | $9.080.000.000 |
| Faaliyet dışı kalemler ve vergiler | -$1.369.000.000 |
| Net kâr | $7.711.000.000 |
| Toplam varlıklar | $90.586.000.000 |
|---|---|
| Nakit | $9.129.000.000 |
| Dönen varlıklar | $29.057.000.000 |
| Toplam yükümlülükler | $81.928.000.000 |
| Kısa vadeli yükümlülükler | $25.489.000.000 |
| Özkaynaklar | $8.658.000.000 |
| Net kâr | $7.711.000.000 |
|---|---|
| Faaliyet nakit girişi | $13.372.000.000 |
| Amortisman ve itfa payları | $5.167.000.000 |
| Hisse bazlı ücretlendirme | $494.000.000 |
| Faaliyet nakit akışı | $9.958.000.000 |
| Faaliyet nakit çıkışı | $3.414.000.000 |
| Kullanılabilir nakit | $21.931.000.000 |
| Dönem başı nakit | $11.973.000.000 |
| Yatırım nakit çıkışı | $1.943.000.000 |
| Capex | $1.858.000.000 |
| Diğer yatırım faaliyetleri | $85.000.000 |
| Finansman nakit çıkışı | $10.859.000.000 |
| Ödenen temettüler | $5.124.000.000 |
| Net borç geri ödemesi | $5.000.000.000 |
| Diğer finansman faaliyetleri | $735.000.000 |
| Dönem sonu nakit | $9.129.000.000 |
| Yatırım nakit akışı | -$1.943.000.000 |
| Finansman nakit akışı | -$10.859.000.000 |
Kaynak: SEC EDGAR · Dosyalandı 2026-02-13 · SEC EDGAR
| İş kategorisine göre gelir | Gelir | Pay | yıllık |
|---|---|---|---|
| Product | $35,1 Mr | %95,6 | %9,7 |
| Product And Service Other | $1,6 Mr | %4,4 | — |
Kaynak: SEC EDGAR · Dosyalandı 2026-02-13 · SEC EDGAR
| Bölgeye göre gelir | Gelir | Pay | yıllık |
|---|---|---|---|
| United States | $26,4 Mr | %71,9 | %10,7 |
| Non Us | $10,3 Mr | %28,1 | %8,1 |
2026-09-08 tarihli analizde kullanılan belirli tarihe ait finansal veriler.
| Dönem | Gelir | EBITDA | Net kâr | Faaliyet nakit akışı | Serbest nakit akışı | Capex | Amortisman ve itfa payları | Hisse bazlı ücretlendirme | Hisse geri alımları | Ödenen temettüler | Net borç ihracı | Yatırım nakit akışı | Finansman nakit akışı | Dönem başı nakit | Dönem sonu nakit | Nakit ve yatırımlar | Toplam borç | Faaliyet marjı | ROIC | WACC | ROIC−WACC farkı |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $23 Mr | $12,5 Mr | $7,7 Mr | $10,4 Mr | $9,6 Mr | $738 Mn | $2,1 Mr | $311 Mn | $3 Mr | $3 Mr | — | -$8,7 Mr | -$2,6 Mr | — | $3,2 Mr | $38,1 Mr | $34,6 Mr | %42,6 | — | %5,7 | — |
| 2017-12-31 | $22,8 Mr | $12,9 Mr | $2 Mr | $11,2 Mr | $10,5 Mr | $664 Mn | $2 Mr | $329 Mn | $3,2 Mr | $3,4 Mr | — | -$4 Mr | -$6,6 Mr | $3,2 Mr | $3,8 Mr | $41,7 Mr | $35,3 Mr | %43,6 | — | %5,7 | — |
| 2018-12-31 | $23,7 Mr | $12,9 Mr | $8,4 Mr | $11,3 Mr | $10,6 Mr | $738 Mn | $1,9 Mr | $311 Mn | $17,8 Mr | $3,5 Mr | — | $14,3 Mr | -$22,5 Mr | $3,8 Mr | $6,9 Mr | $29,3 Mr | $33,9 Mr | %43,2 | — | %6,4 | — |
| 2019-12-31 | $23,4 Mr | $12,6 Mr | $7,8 Mr | $9,2 Mr | $8,5 Mr | $618 Mn | $2,2 Mr | $308 Mn | $7,7 Mr | $3,5 Mr | — | $5,7 Mr | -$15,8 Mr | $6,9 Mr | $6 Mr | $8,9 Mr | $29,9 Mr | %41,4 | — | %5,7 | — |
| 2020-12-31 | $25,4 Mr | $13 Mr | $7,3 Mr | $10,5 Mr | $9,9 Mr | $608 Mn | $3,6 Mr | $330 Mn | $3,5 Mr | $3,8 Mr | — | -$5,4 Mr | -$4,9 Mr | $6 Mr | $6,3 Mr | $10,6 Mr | $33 Mr | %35,9 | — | %3,2 | — |
| 2021-12-31 | $26 Mr | $11,3 Mr | $5,9 Mr | $9,3 Mr | $8,4 Mr | $880 Mn | $3,4 Mr | $341 Mn | $5 Mr | $4 Mr | — | $733 Mn | -$8,3 Mr | $6,3 Mr | $8 Mr | $8 Mr | $33,3 Mr | %29,4 | — | %3,7 | — |
| 2022-12-31 | $26,3 Mr | $12,2 Mr | $6,6 Mr | $9,7 Mr | $8,8 Mr | $936 Mn | $3,4 Mr | $401 Mn | $6,4 Mr | $4,2 Mr | $6,9 Mr | -$6 Mr | -$4 Mr | $8 Mr | $7,6 Mr | $9,3 Mr | $38,9 Mr | %36,3 | — | %6,0 | — |
| 2023-12-31 | $28,2 Mr | $7,9 Mr | $6,7 Mr | $8,5 Mr | $7,4 Mr | $1,1 Mr | $4,1 Mr | $431 Mn | $0 | $4,6 Mr | $26,3 Mr | -$26,2 Mr | $21 Mr | $7,6 Mr | $10,9 Mr | $21,9 Mr | $64,6 Mr | %28,0 | — | %5,7 | — |
| 2024-12-31 | $33,4 Mr | $13,4 Mr | $4,1 Mr | $11,5 Mr | $10,4 Mr | $1,1 Mr | $5,6 Mr | $530 Mn | $200 Mn | $4,8 Mr | -$3,6 Mr | -$1 Mr | -$9,4 Mr | $10,9 Mr | $12 Mr | $12 Mr | $60,1 Mr | %21,7 | — | %6,5 | — |
| 2025-12-31 | $36,8 Mr | $16,9 Mr | $7,7 Mr | $10 Mr | $8,1 Mr | $1,9 Mr | $5,2 Mr | $494 Mn | $0 | $5,1 Mr | -$5 Mr | -$1,9 Mr | -$10,9 Mr | $12 Mr | $9,1 Mr | $9,1 Mr | $54,6 Mr | %24,7 | — | %5,9 | — |
Amgen Inc. (AMGN) trades at 18.2x forward earnings against a peer median of 15.5x. Its EV/EBITDA of 16.2x compares with a peer median of 13.5x. The comparison uses 4 peers: Johnson & Johnson, Biogen Inc., Pfizer Inc. and UnitedHealth Group Incorporated, as of 2026-09-08.
Industry capital spending equaled 1.1% of revenue and 0.8 times depreciation as of 2026-09-01.
The demand-led upside case requires FY2027 revenue to exceed its $40.21 billion mean while adjusted earnings remain strong.
Customer repricing or product weakness could reduce sales quickly because three customers supplied 77% of FY2025 revenue.
Amgen enters this cycle with positive cash generation, concentrated customers, and substantial debt. Demand delivery matters more than an assumed industry capacity upswing.35
Start gradually because the report-date price is below Fair value, while FY2027 forecast ranges remain wide.13
Add only within portfolio limits while revenue, earnings, and cash remain on track.15
Use a smaller initial position because customer concentration and debt can amplify an operating miss.36
Buy, with staged exposure tied to FY2027 delivery.
The report-date price of $437.23 is below Fair value of $492.07, while positive estimates and cash generation support measured upside.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Cash generated per dollar of reported profit at or below 0.8 would weaken the independent support for adjusted earnings.
A contraction would pass product weakness into consolidated sales, then pressure operating profit because the smaller other-revenue line offers little offset.
Güncel:FY2025 product revenue of $35.15 billion.
Şu durumda uyarAt least a 5% annual contraction within 24 months.
A higher required return would reduce the present worth of distant earnings, especially where value depends heavily on results after FY2027.
Güncel:7.6252% as of 2026-09-08.
Şu durumda uyarMore than two percentage points above the baseline within 12 months.
Weaker cash generation would make reported profit less dependable and leave less cash for capital spending, dividends, and debt service.
Güncel:FY2025 ratio of 1.2914.
Şu durumda uyarAt or below 0.8 for a trailing fiscal year within 24 months.
A sub-threshold outcome would show slower demand before longer-range assumptions begin, forcing lower revenue and earnings paths after FY2027.
Güncel:Approved FY2027 path of 3.26%.
Şu durumda uyarBelow 3% for FY2027.
| high |
| Through FY2027 |
| Fade growth after the explicit forecast window unless product revenue continues expanding.6 |
Limitation: Terminal value is 65.2% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
Under the moderate discount rate, $173 comes from forecast-period earnings and $277 from the long-term value, totaling $450.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Limitation: Terminal value is 75.3% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Stronger revenue, earnings, and cash would extend growth duration without requiring a hyper-growth assumption. A low-end FY2027 earnings result would disconfirm this path.
Delivery supports value per share; a low-end breach shortens the earnings path.1
Product weakness would reach consolidated sales quickly.6
Lower concentration would reduce repricing and customer-loss exposure.6
Strong cash backing funds investment and debt service.
| $41.41B |
| $42.57B |
| $43.68B |
| Operating income | $9.62B | $9.94B | $10.23B | $10.52B | $10.79B |
| NOPAT | $8.31B | $8.58B | $8.84B | $9.09B | $9.32B |
| Residual cash after reinvestment policy | $8.31B | $8.58B | $8.84B | $9.09B | $9.32B |
| Revenue growth | 6.0% | 3.3% | 3.0% | 2.8% | 2.6% |
| Operating margin | 24.7% | 24.7% | 24.7% | 24.7% | 24.7% |
| Tax rate | 13.6% | 13.6% | 13.6% | 13.6% | 13.6% |
| Reinvestment rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
| Diluted shares | 544.01M | 546.03M | 548.06M | 550.09M | 552.13M |
| EPS | $19.37 | $24.41 | $24.96 | $25.48 | $25.96 |
| Net margin | 27.1% | 33.1% | 33.0% | 32.9% | 32.8% |
| Implied net income | $10.54B | $13.33B | $13.68B | $14.02B | $14.34B |
Total debt was $57.30 billion on 2026-09-07.
Weaker cash generation or higher refinancing costs could crowd out reinvestment.
| Marj |
|---|
| AMGN | Amgen Inc. | $236.4B | 18.2x | 6.2x | 16.2x | 91.5% | — |
| JNJ | Johnson & Johnson | 22.4x | 6.8x | 19.8x | 25.7% | 29.2% | |
| BIIB | Biogen Inc. | 13.3x | 3.3x | 11.8x | 4.6% | 25.1% | |
| PFE | Pfizer Inc. | 9.8x | 2.5x | 8.4x | 5.0% | 27.9% | |
| UNH | UnitedHealth Group Incorporated | 17.7x | 0.8x | 15.2x | 14.2% | 7.1% |
